Pfizer's blood cancer drug meets main goal in late-stage trial

New Photo - Pfizer's blood cancer drug meets main goal in late-stage trial

Pfizer&x27;s blood cancer drug meets main goal in latestage trial ReutersWed, April 29, 2026 at 11:42 AM UTC 0 FILE PHOTO: A logo of Pfizer at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov//File Photo April 29 (Reuters) Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a latestage trial that tested the bloodcancer treatment in patients who received at least one prior ​line of treatment. Here are further details on the trial: • Elrexfio has the U.S.

Pfizer's blood cancer drug meets main goal in late-stage trial

ReutersWed, April 29, 2026 at 11:42 AM UTC

0

FILE PHOTO: A logo of Pfizer at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov//File Photo

April 29 (Reuters) - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ‌cancer treatment in patients who received at least one prior ​line of treatment.

Here are further details on the trial:

• Elrexfio has the U.S. Food and Drug Administration's accelerated approval for treating patients with multiple myeloma ‌who have received at ⁠least four prior lines of treatment.

• Multiple myeloma is a cancer of the ⁠plasma cells, a type of white blood cell in the bone marrow that helps fight infection.

• Pfizer ​said ​the drug showed clinically ​meaningful improvement in progression ‌free survival, or living without the disease worsening, when compared to standard of care treatment.

Advertisement

• The trial remains ongoing to assess overall survival, a key secondary goal, as the data was not yet ‌available at the time of ​this interim analysis, the company ​said.

• The company ​said the trial data will be ‌discussed with global health authorities.

• ​Pfizer recorded Elrexfio ​sales of $304 million in 2025.

• Multiple myeloma accounts for roughly 1% to 2% of all ​cancers and ‌10% of blood cancers. Over 32,000 new cases ​are diagnosed annually in the US.

(Reporting by ​Christy Santhosh in Bengaluru)

Original Article on Source

Source: "AOL Breaking"

Read More


Source: Breaking

Published: April 29, 2026 at 07:54AM on Source: PRIME TIME

#ShowBiz#Sports#Celebrities#Lifestyle

 

PRIME SKY © 2015 | Distributed By My Blogger Themes | Designed By Templateism.com